Articles tagged with Pancreas
Researchers identified estrogen-related receptor gamma (ERR γ) as crucial for preventing pancreatic auto-digestion in mice. In humans, lower levels of ERR γ were found in cells affected by pancreatitis. These findings suggest new therapies regulating ERR γ activity could help prevent or treat these conditions.
A team from UNIGE demonstrates that stem cells giving rise to beta cells cease to exist after birth, and defines the 'identity card' of other hormone-producing cells. This discovery has significant implications for developing cell-based therapies to treat diabetes.
Researchers found that alterations in gut microbiota can help treat pancreatic and hormonal dysfunction in diabetes patients. The study showed that antibiotics treatment can improve insulin sensitivity and reduce glucose intolerance in obese mice and humans.
The Lustgarten Foundation has awarded Career Development Grants to Pingping Hou and Edwin Manuel to fund research on pancreas cancer. Their projects focus on immune cell populations and nutrient uptake by cancer cells, aiming to develop novel therapies.
CHOP researchers have developed a targeted treatment that controls blood sugar in patients with hyperinsulinism, a genetic disease. The study found exendin-(9-39) reduces likelihood of fasting hypoglycemia by 76% and protein-induced hypoglycemia by 82%
Researchers identified peripheral tissues as source of blood amyloid beta, which regulates blood glucose levels and suppresses insulin secretion. The study suggests a possible mechanism linking type 2 diabetes to Alzheimer's disease development.
A multicenter study found relatively high interobserver agreement for chronic pancreatitis findings in children using both CT and MRI. However, subjective findings like atrophy showed moderate agreement, emphasizing the need for standardized criteria.
Researchers developed genetic modifications to increase stress resistance and immune evasion in stem cell-derived beta cells, leading to improved survival rates. The study suggests a potential breakthrough for treating type 1 diabetes through transplantation of these cells.
Researchers have revealed that during Type 1 Diabetes development, pancreatic duct cells reprogram to suppress autoimmune T cell responses. This discovery advances understanding of the disease by creating a map of pancreatic islet cells over time.
Researchers at Scripps Research have identified an experimental compound called IXA4 that activates a natural signaling pathway to protect against obesity-driven metabolic changes. This approach shows promise for preventing or treating type 2 diabetes.
A new artificial pancreas system has been shown to be safe and effective in managing blood sugar levels in very young children with type 1 diabetes. The hybrid closed-loop system, CamAPS FX, reduced average blood sugar levels and improved glucose control without increasing the risk of hypoglycemia.
Researchers discovered a new hormone, fabkin, that regulates metabolism and controls insulin production in pancreatic beta cells. Blocking fabkin's activity prevented the development of both forms of diabetes in mice, suggesting its potential as a therapeutic target.
Scientists at Tokyo University of Science have developed a novel polymer-based hydrogel that can prevent postoperative pancreatic fistulae, a frequent complication of pancreatic surgery. The Exceval hydrogel shows great promise for clinical applications due to its adjustable properties and high absorption abilities.
Researchers at Karolinska Institutet found that certain bacteria from the digestive system can cause damage to pancreatic cells, increasing the risk of malignant tumours. The study suggests that antibiotics could prevent this damage, offering a potential prophylactic intervention.
A new type of PRRT, <sup> 177 </sup> Lu-DOTA-LM3, has been shown to be safe and effective in treating neuroendocrine neoplasms. The therapy achieved complete remission in some patients and was well-tolerated by most patients.
A new study has identified the CCR2 gene as a key player in the progression of type 1 diabetes. The research found that lower blood levels of CCL-2, a ligand for CCR2, were associated with increased immune cell recruitment to the pancreas, leading to islet cell destruction.
Researchers discovered that pancreatic injury leads to the formation of new cell types that can give rise to cancerous mutations. The study provides a valuable resource for understanding the processes behind pancreatic cancer and potential therapeutic targets.
A multi-center study demonstrated improved overall survival and quality of life for inoperable pancreatic cancer patients treated with MRIdian SMART, with a median survival of 26 months. The treatment showed low rates of major adverse events and was more effective than standard radiation therapy.
Researchers at Purdue University have successfully reversed pancreatic cancer progression in a new model called the acinus, which produces digestive enzymes. The study found that reactivating the PTF1a gene in cancerous cells converted them back into normal cells, revealing a potential path to treating pancreatic cancer.
Researchers developed an experimental device to improve blood sugar control in HI patients. The bihormonal bionic pancreas (BHBP) helps maintain stable glucose levels without human error in calculating doses.
Researchers at Vanderbilt University Medical Center developed a standardized MRI protocol for pancreatic imaging, enabling reproducible measurements across different MRI hardware and software. The study demonstrates potential for incorporating MRI into multisite clinical trials, advancing diabetes research and treatment.
Researchers found that a gene called REST is crucial for boosting insulin-producing cells during early pancreas development. Inactivating this gene increased the number of insulin-producing cells, which were maintained into adulthood in mice.
A new artificial pancreas has been successfully trialled in outpatients with type 2 diabetes, showing improved blood sugar control and reduced risk of low blood sugar levels. The device can automate insulin delivery using digital technology, allowing for more effective management of the condition.
Experts at the University of Birmingham argue that patients with type one diabetes need clear professional guidance to use 'Do-It-Yourself' artificial pancreas systems. The lack of legal, regulatory, or ethical guidance for clinicians has led to doctors being cautious about discussing DIY APS with patients.
A new AI algorithm enabled a fully automated artificial pancreas system to achieve improved glucose control without manual input of meal or exercise information. This breakthrough could lead to more efficient and hassle-free diabetes management.
Researchers at La Jolla Institute for Immunology discovered that even healthy individuals have high numbers of preproinsulin-specific T cells in their pancreas. These cells are believed to be the prime suspects in triggering the autoimmune response that causes type 1 diabetes.
A new study reveals that reversing type 2 diabetes can restore the pancreas to a normal size and shape, improving insulin function. After 2 years of weight loss, responders experienced significant growth in pancreas volume and fat reduction, while non-responders showed no change.
A new artificial pancreas system has been shown to prevent hypoglycemia during and after heavy exercise in people with type 1 diabetes. The study, published in the Journal of Clinical Endocrinology & Metabolism, found that the system performed well and was safe compared to standard therapy.
The Control-IQ system, manufactured by Tandem Diabetes Care, safely and effectively manages blood glucose levels in children with type 1 diabetes. The study found that the artificial pancreas did a better job keeping the children's blood glucose within the target range.
The study found that youth using the artificial pancreas system had significant improvements in blood glucose control, including a 7% improvement during the daytime and a 26% improvement at night. The technology improved overall time-in-range by nearly 11%, translating to more hours per day in a healthy range.
A clinical trial found that a new artificial pancreas system improved blood glucose control in children aged 6-13, achieving 7% daytime improvement and 26% nighttime control. The technology replaces traditional testing and insulin delivery, providing greater convenience and safety.
A new study from La Jolla Institute for Immunology found that blocking nerve signals to the pancreas could stop patients from ever developing type 1 diabetes. The researchers used a mouse model and discovered that blocking sympathetic nerve signals protected mice from beta cell death.
Researchers have developed a therapy using engineered T cells to target and treat type 1 diabetes by restoring balance in the pancreas. The treatment involves genetically engineering a patient's own T cells to function like normal regulatory T cells, which then help suppress the overactive immune response.
A team of McGill University researchers has created an artificial pancreas system that significantly improves glucose control, enhancing quality of life for individuals with type 1 diabetes. The system, which combines insulin and pramlintide, has shown promising results in minimizing glucose highs and lows.
Studies in mice and humans with pancreatitis reveal a link between FGF21 deficiency and the disease. Replacement therapy with FGF21 may reverse conditions in about 24 hours, offering a new treatment strategy for acute pancreatitis.
The FDA has approved an artificial pancreas system that automatically monitors and regulates blood glucose levels in people with type 1 diabetes. The system, developed by the University of Virginia, uses a continuous glucose sensor and insulin pump to provide seamless integration and automatic insulin dose adjustment.
Scientists have observed people developing Type 2 diabetes due to liver fat over-spilling into the pancreas. A study showed that individuals can reverse the condition through diet and weight loss, with nearly nine out of ten participants achieving remission.
A team of scientists from Tokyo University of Science has made a breakthrough in understanding the inflammation mechanism in IgG4-related disease. They found that cytotoxic T lymphocytes (CTLs) and T follicular helper cells (Tfh cells) are necessary for pancreatic inflammation, and propose Janus kinase (JAK) as a suitable therapeutic t...
A multi-center trial found that the artificial pancreas system improved users' blood glucose control throughout the day and overnight, reducing hyperglycemia and hypoglycemia events. The study showed significant benefits of the new system over existing treatments, with no severe hypoglycemia events occurring in either group.
A multicenter randomized clinical trial found that the new artificial pancreas system improved participants' blood glucose control throughout the day and overnight, outperforming existing treatments. The system significantly increased time with target blood glucose levels and showed improvements in other diabetes control measurements.
A research team has created a better way to grow an organoid model of the liver, bile duct and pancreas using human pluripotent stem cells. The resulting organoid bears a striking resemblance to its corresponding organs and demonstrates the potential for personalized modeling in studying organ development and disease.
A new artificial pancreas system improved participants' blood glucose control throughout the day and overnight, reducing the risk of low blood sugar levels. The system's advanced algorithms and safety features enabled users to achieve near-normal blood sugar levels every morning.
A new artificial pancreas system has been shown to improve blood glucose control throughout the day and overnight, offering a significant advantage over existing treatments for people with type 1 diabetes. The system, which automatically monitors and regulates blood glucose levels, was more effective than traditional therapies in achie...
A new artificial pancreas system improved blood glucose control throughout the day and overnight, reducing time in range for high and low glucose levels. The system also showed improvements in hemoglobin A1c and other measurements related to diabetes control compared to current technology.
Researchers at Technical University of Munich have discovered a specific neuroenzyme responsible for analgesics resistance in chronic pancreatitis. The team found that targeting this enzyme, nNOS, with an existing inhibitor reduces pain perception in animal models, offering new hope for pancreatic patients
Researchers created a human pancreas on a chip that can mimic the human pancreas and potentially help find therapeutic measures to manage glucose imbalance in people with cystic fibrosis. The device was used to study CF-related diabetes and type 1/2 diabetes, opening new possibilities for disease research.
Patients with Type 1 diabetes who are obese often face denied pancreas transplantation due to high infection risks. However, robotic pancreas transplantation has shown promising results, reducing blood loss and surgical complications while improving patient outcomes.
Researchers found that mice eating a high-fat diet who fasted every other day had reduced pancreatic fat and lower blood sugar levels. This suggests that intermittent fasting may be a therapeutic approach to prevent type 2 diabetes by reducing fat accumulation in the pancreas.
Researchers discovered a key clue into pancreas development by studying rare patients born without a pancreas. A previously unexpected pathway was identified, confirming its role in human and mouse pancreas formation.
The study shows that Wt1 gene deletion causes deterioration of the pancreas and activates stellate cells, which play a key role in pancreatic cancer progression. The results suggest Wt1 gene is necessary for normal pancreas maintenance and repair after damage.
A new study reveals that the development of progenitor cells depends on protein quantity and interaction with other cells. Cells with high P120ctn expression remain in the central part of the pancreas, while those with low expression migrate to the peripheral area, where they acquire their final fate.
Researchers at MIT have developed a way to measure oxygen levels of pancreatic islet cells over long periods, enabling them to predict which implants will be most effective in treating diabetes. This breakthrough could lead to better designs for artificial pancreas systems.
Researchers have made significant progress with UVA's artificial pancreas, a device that automates blood-sugar level monitoring and insulin injection. The International Diabetes Closed Loop Trial has provided early results from its nationwide clinical trial, examining the algorithm's use in smartphone apps and embedded devices.
The interoperable Artificial Pancreas System smartphone app has shown improved time in the target glucose range and a statistically significant reduction in time below 70mg/dL. The study suggests that this system could provide personalized care for patients with diabetes, offering flexibility and convenience.
Researchers at Stanford University have developed a zinc-based regenerative drug that selectively targets insulin-producing cells in the pancreas, potentially paving the way for more appealing alternatives to insulin injections. The method uses chelation to deliver a drug to beta cells, which have a strong affinity for zinc.
Researchers studied pancreas duct formation in mice and found that the network resembles road networks, with stronger ducts expanding and weaker ones shrinking. This study may lead to better understanding and treatment of cystic fibrosis and other diseases involving abnormal duct formation.
A pilot study found crystalline particles of titanium dioxide in pancreas specimens with Type 2 diabetes, suggesting a possible link between the white pigment and the disease. The study suggests that increased use of titanium dioxide may contribute to the global rise in T2D cases.
Researchers at Oregon State University have developed transparent transistors that can be fabricated onto curved surfaces, paving the way for improved diabetes therapy. This innovation is a key step towards creating an artificial pancreas, which can detect blood sugar levels and transmit information to a wearable insulin pump.
A review of 41 trials involving over 1000 people with type 1 diabetes found that artificial pancreas systems provided almost two and a half extra hours of normal blood glucose levels per day. The treatment also reduced time spent in both hyperglycaemia and hypoglycaemia compared to other types of insulin-based therapy.
Researchers at CNIO discovered that a gene controlling inflammation also increases pancreatic cancer risk. The study suggests new strategies for prevention and detection of the disease.